Tests a clot-removal device during artery opening in front-wall heart attack

Trial details

Who runs it

Ceric Sàrl

Trial code

NCT06887413

Record updated

21 April 2026

Original description

The aim of this study is to evaluate the impact of sustained thrombectomy with INDIGO ASPIRATION SYSTEM using CAT RX versus no thrombectomy during primary percutaneous coronary intervention (PPCI) on microvascular obstruction and infarct size, as measured by cardiovascular magnetic resonance (CMR) between 3 and 5 days post PPCI, in patients with anterior STEMIRead full original descriptionShow less

TACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial.

The aim of this study is to evaluate the impact of sustained thrombectomy with INDIGO ASPIRATION SYSTEM using CAT RX versus no thrombectomy during primary percutaneous coronary intervention (PPCI) on microvascular obstruction and infarct size, as measured by cardiovascular magnetic resonance (CMR) between 3 and 5 days post PPCI, in patients with anterior STEMI

Inclusion: Age >18 and <75 years old; Acute anterior STEMI with ≥2 mm in two (2) or more contiguous anterior leads or ≥4 mm total ST-segment deviation sum in the anterior leads V1-V4 AND anterior wall motion abnormality noted on a diagnostic quality left ventriculogram or echocardiogram; Culprit lesion proximal or mid LAD at coronary angiography; TIMI thrombus grading > 3 or TIMI flow 0 after guidewire crossing the lesion; Patient presents to the hospital between 1 - 6 hours of ischemic pain onset; Patient indicated for primary percutaneous coronary intervention (PPCI).

Exclusion: Unwitnessed cardiac arrest OR ≥30 minutes of cardiopulmonary resuscitation (CPR) prior to enrolment OR any cardiac arrest with impairment in mental status, cognition or any global or focal neurological deficit; New onset of stroke symptoms and NIHSS >2, prior to index procedure; Administration of fibrinolytic therapy within 24 hours prior to enrolment; History or known hepatic insufficiency prior to catheterization; Undergoing a renal replacement therapy; Known or evidence of prior MI, including pathologic Q-waves in non-anterior leads; Prior coronary artery bypass graft surgery (CABG) or LAD PCI; History of heart failure (documented history of EF <40% or documented hospitalization for HF within 1 year prior to screening; Prior aortic valve surgery or TAVR; History of stroke/TIA within 3 months prior to screening; STEMI due to stent thrombosis; Active severe bleeding; Severe hepatic/kidney impairment; Inferior STEMI or suspected right ventricular failure; Acute cardiac mechanical complication: LV-free wall rupture OR interventricular septum rupture OR acute mitral regurgitation; Medical Conditions \& History:; Suspected systemic active infection; Chronic obstructive pulmonary disease (COPD) with home oxygen therapy or on chronic steroid therapy; Cardiogenic shock defined as systemic hypotension (systolic BP <90 mmHg or the need for inotropes/pressors to maintain a systolic BP >90 mmHg), plus one (1) of the following: any requirement for pressors / inotropes prior to arrival at the catheterization laboratory, clinical evidence of end-organ hypoperfusion, or use of IABP or any other mechanical circulatory support device; Contraindication to perform MRI or use gadolinium [creatinine clearance (CrCl) <30 mL/min, non-compatible implant, claustrophobia]; Cardiovascular history; Unable to give Informed consent; Life expectancy < 1 year; Contraindication to PCI; Spontaneous coronary aretery dissection; Patient undergone any kind of maneuvers to restore flow before randomization; Known intolerance to aspirin, clopidogrel, ticagrelor, heparin, contrast media; Severe valvulopathy; Suspected or known pregnancy; Left bundle branch block (new or old).

ClinicalTrials.gov NCT06887413